Multimodality management for barcelona clinic liver cancer stage C hepatocellular carcinoma

Liver Cancer

Volumn 3, Issue 3-4, 2014, Pages 405-416

  Choi, Chihwan ^a   Choi, Gi Hong ^b   Kim, Tae Hyun ^c   Tanaka, Masatoshi ^d   Meng, Mao Bin ^e   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d Yokokura Hospital   (Japan)

^e TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Advanced stage; Hepatocellular carcinoma; Multimodality management; Staging systems

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVISORY COMMITTEE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPAIN;

EID: 84922102782     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000343861     Document Type: Review

References (62)

1. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. J Hepatol 2012;56(Suppl 1):S75-S87.
2. European Association For The Study Of The Liver, European Organisation For Research, Treatment Of Cancer: Easl-eortc clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haüssinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SI, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL: Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81(Suppl 1):158-164.
6. Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY: Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81(Suppl 1):134-140.
7. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK: Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010;28:2889-2895.
8. Kokudo N, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44(Suppl 19):119-121.
9. Korean Liver Cancer Study Group and National Cancer Center, Korea: Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423.
10. Lee JM, Han KH: Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach-Asian perspective. Oncology 2010;78(Suppl 1):167-171.
11. Kudo M, Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78(Suppl 1):154-166.
12. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
13. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH, Asian Oncology Summit: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-1118.
14. Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL: Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620.
15. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24:806-814.
16. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012;1:41-50.
17. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
18. Jihye C, Jinsil S: Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer 2012;1:216-225.
19. Hsu HC, Chen TY, Chiu KW, Huang EY, Leung SW, Huang YJ, Wang CY: Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42.
20. Lau WY, Lai EC: Salvage surgery following downstaging of unresectable hepatocellular carcinoma-a strategy to increase resectability. Ann Surg Oncol 2007;14:3301-3309.
21. Han KH, Seong J, Kim JK, Ahn SH, Lee Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008;113:995-1003.
22. Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM: Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiother Oncol 2009;92:184-194.
23. Seong J: Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J 2009;50:601-612.
24. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, Seong J, Han KH, Lee JT: The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci 2009;24:242-247.
25. Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C, Jiang GL: Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013;329:109-117.
26. Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim Y, Ahn SH, Chon CY, Han KH: Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS ONE 2013;8:e77240.
27. Liapi E, Geschwind JF: Combination of local transcatheter arterial chemoembolization and systemic antiangiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer 2012;1:201-215.
28. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595.
29. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-137.
30. Ueda H, Fukuchi H, Tanaka C: Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (review). Oncology Letters 2012;3:259-263.
31. Klein J, Dawson LA: Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013;87:22-32.
32. Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M, Terashita K, Sakuhara Y, Abo D, Tsukuda Y, Tsunematsu S, Hige S, Kato M, Shirato H, Asaka M: Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol 2011;26:1123-1132.
33. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
34. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB: Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009;29:1291-1298.
35. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P: Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993;71:62-65.
36. Higuchi T, Kikuchi M, Okazaki M: Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 1994;73:2259-2267.
37. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE: Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999;43:393-397.
38. Seong J, Park HC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO: Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 2000;47:1331-1335.
39. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196.
40. Oh D, Lim H, Park HC, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC, Lim HK, Lee WJ, Rhim H, Shin SW, Park KB: Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010;33:370-375.
41. Hawkins MA, Dawson LA: Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-1663.
42. Xu LT, Zhou ZH, Lin JH, Chen Z, Wang K, Wang P, Zhu XY, Shen YH, Meng ZQ, Liu LM: Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Eur J Surg Oncol 2011;37:245-251.
43. Yu JI, Park HC, Lim H, Kim CJ, Oh D, Yoo BC, Paik SW, Kho KC, Lee JH: Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci 2012;27:736-743.
44. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung H, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-5431.
45. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
46. Lei J, Yan L: Comparison between living donor liver transplantation recipients who met the milan and ucsf criteria after successful downstaging therapies. J Gastrointest Surg 2012;16:2120-2125.
47. Yu CY, Ou HY, Huang TL, Chen TY, Tsang LL, Chen CL, Cheng YF: Hepatocellular carcinoma downstaging in liver transplantation. Transplant Proc 2012;44:412-414.
48. Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim do Y, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY: Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. OncoTarget Ther 2013;6:755-759.
49. Tang ZY, Zhou XD, Ma ZC, Wu ZQ, Fan J, Qin LX, Yu Y: Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3:495-498.
50. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C: Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-665.
51. Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, Sun HC, Wang BL, Zhang JY, Jiang GL, Wang YQ: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443.
52. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ: Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011.
53. Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H, Hosoi Y, Shiina S, Omata M, Makuuchi M, Ohtomo K: Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005;11:7237-7241.
54. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ: Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426.
55. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-575.
56. You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, Choi IB, Lee DH, Chun HJ, Choi BG: Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol 2007;13:378-386.
57. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119.
58. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, Jang HS, Kim MS, Chie EK, Kim JH, Nam TK, Lee HS, Han CJ: A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009;29:147-152.
59. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD, Lichter AS: The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-788.
60. Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, Lee WJ, Park SJ, Hong EK, Kim CM: Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-231.
61. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM: Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819.
62. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA: Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-1639.